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Background
Environmental pollutants and toxicants take many forms as they 
can be chemical, biological and physical in nature. Urbanization 
and industrialization have led to increasingly high amounts of waste 
production and discharge into the environment. Everyday living places 
people in constant contact with environmental toxicants through 
contaminated mediums of air, water and land. The health implications 
suffered include much of which is encountered through air pollution. 
Respiratory ailments such as asthma allergies, and eye and nasal passage 
irritation are common symptoms of exposure. The immune, endocrine 
and reproductive systems are susceptible to harm as well. It has been 
documented that exposure to particulates are associated with morbidity 
and mortality risks from many diseases, chronic illnesses and even 
cancer [1]. Increasing lines of evidence support that neurodegenerative 
disease such as Parkinson disease (PD) may be associated with multiple 
etiological components including genetic factors (i.e., NFE2L2, SNCA, 
LRRK2, Parkin, PINK, DJ-1, and ATP13A2) [2-6], and environmental 
factors (i.e., smoking, aging, pesticide, herbicide, infections, or various 
environmental chemicals) [7-10]. 
The mitochondria are special organelles located within cells that 
contain their own DNA as well as important organelle to maintain cell 
homeostasis reflect responsible for biochemical processes of respiration 
and energy production. They are essentially the power house of the cell 
by producing ATP as a driving fuel for the cells [11]. Interestingly, the 
mitochondria are the focal point for idiopathic diseases and genetic 
diseases due to their sensitivity to environmental insult. In previous, 
scientific reports are making connections between mitochondrial 
dysfunction include mutation and resulting health conditions such 
as Parkinson disease (PD), Alzheimer disease (AD), and autism 
and even cardiovascular illness [12-15]. Perier and Vila [16] have 
described that mitochondria have important cellular functions that 
include oxidative phosphorylation, regulation of calcium homeostasis, 
lysosomal impairment, and control of program cell death. Although the 
mitochondria are equipped for such complex roles, they seem to have 
susceptibilities to mutations from environmental factors that can lead 
to certain human diseases.
It remains unclear how environmental factors and genetic disposition 
may attribute to development of idiopathic neurodegenerative disorders. 
It is noteworthy, that there is evidence to support PD etiology due to 
mitochondria dysfunction.  This could be linked idiopathically to PD 
pathogenesis through alteration of functional molecular mechanisms 
such as protein Parkin, α-Synuclein, aberrant genetic modification such 
as mutant PARK2 and parkin mutations in the patient samples [17-22].
Parkinson’s disease (PD) is a neurodegenerative disease that slowly 
causes dopaminergic neurons in the midbrain to die. This gradual loss 
of dopamine causes loss of coordinating muscle movements. Perier and 
Villa [16] have also stated that “defective mitochondrial respiration has 
long been associated with the pathogenesis of PD”. The evidence for 
this claim came about when drug abusers were exposed to 1-methly-
4-phenyl-1,2,3,4-tetrahydropyridine (MPTP).  MPTP selectively 
kills dopaminergic neurons of the susbstania nigra pars compacta 
(SNpc) [16]. In previous studies, it has been shown that blockade of 
Complex I has reduced Complex I activity in the brain and skeletal 
muscles of those with Parkinson’s disease. Other alterations of the 
mitochondria that can cause this neurodegenerative disease includes 
increased production of mitochondria reactive oxygen species (ROS), 
ROS mediated mitochondria DNA (mtDNA) damage, bioenergetics 
failure, and activation of mitochondrial apoptotic pathways [16]. All 
of this evidence supports the premise that dysfunctions in the dynamic 
mitochondria can definitely cause Parkinson’s symptoms to develop 
in organisms. Just like reports of mutations in the mitochondria the 
environment can also alter the mitochondria and increase the risk of 
Parkinson’s disease [22,23]. 
In accordance with previous reports, it has also been shown that 
exposure to certain environmental factors can cause malfunctions in the 
mitochondria leading to certain human diseases. The combined effect 
of environmental influences and mitochondrial susceptibilities may 
be contributing factors to Parkinson’s disease.  According to National 
Institute of Environmental Health Science (NIEHS, 2016), “pesticide 
exposure is associated with an increased risk of developing Parkinson’s 
disease”. Those who come in to contact with pesticides are more prone 
to develop Parkinson’s disease. Occupational use of two specific of 
pesticides, rotenone and paraquat poisoning, are documented to be 
associated with PD [24] “Rotenone directly inhibits the function of 
the mitochondria, while paraquat increases the production of certain 
damaging oxygen derivatives” (NIEHS, 2016). This highlights the 
cellular consequence of mitochondrial malfunction in individuals with 
specific pesticide exposure, especially rotenone and paraquat, and the 
subsequent increased risk of developing neurodegenerative disease.   
Parkinson’s disease (PD) is still undergoing tremendous research 
to understand how genes, environment, and mitochondria all interact. 
Currently there are no standard diagnostic tests for PD, however 
neurological history and physical examination do determine the presence 
of disease in an individual. Although there is no cure for PD, many 
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treatments exist to help minimize the symptoms. Carbidopa-levodopa 
is the most effective treatment in which the chemical passes through 
the brain and converts into dopamine [25]. Conjugated Dopamine or 
combination pharmacological agents with cysteine can help stabilize 
the effects of PD by preventing the oxidation process of dopamine 
to dopamine o-quinone, aminochrome and 5,6-indolequinone. This 
treatment seems to be effective against disease progression [26,27]. 
Unfortunately long term treatment with levodopa (L-DOPA) will cause 
tardive dyskinesia in addition to having a malfunctioning nigrostriatal 
dopaminergic system [28,29]. Another treatment involves the use of is 
MAO-B inhibitors. There are several reports documenting that these 
inhibitors could prevent the breakdown of dopamine by inhibiting 
the brain enzyme monoamine oxidase (MAO-B) [30-32]. This drug 
can prevent metabolism of dopamine. Parkinson’s disease (PD) is a 
difficult neurodegenerative disease to control. Treatments are limited 
to delaying disease progression and treating the symptoms. Utilizing 
advanced technologies can lead to invaluable insight of rapid disease 
progression and what biological processes need to be targeted in order 
to prevent PD from occurring.  
Problem Statement
Of particular interest is Parkinson's disease. The exact etiology 
remains unclear but a common thread of thought it that there are 
combined causal roots of genetics and environment. Approximately 
5-10% cases are known to be due to genetic causes (monogenic form) 
in PD [33,34]. Environmental risks are from a number of sources that 
include most commonly pesticide exposure, living in rural settings, 
well water consumption, herbicide exposure and living in proximity to 
industrial plants or quarries. Bellou et al. reported that environmental 
factors such as dietary factors, drugs, medical history or comorbid 
diseases, exposure to toxic environmental agents and habits have been 
substantially associated with Parkinson's disease in 21 of 75 meta-
analyses (more than 1000 cases) [35].
Parkinson's disease affects 1% of people over the age of 60. The 
incidence is 5 to 24 cases per 100,000 and prevalence is anywhere from 
66 to 187 cases per 100,000. Most studies yield a prevalence of 120 cases 
per 100,000. Both disease incidence and prevalence increase with age; 
the average age of onset is 60 years old. Early onset of disease under the 
age of 40 is uncommon but possible. It is also 1.5 times more likely to 
occur in men than in women [36,37].
Mitochondria malfunction can be linked to certain neurological 
disorders which might be considered as a significant role in the 
pathogenesis of PD.  Those with susceptible genes are more prone to 
developing the disease and experiencing rapid progression if exposed 
to certain environmental factors.
Methodology
Since the advent of enhanced technologies, scientists have been able 
to use high sequencing techniques (i.e., next gene sequencing, NGS and 
RNA sequencing), microarrays, and many other technologies such as 
gene editing technology to analyze the function of the body at molecular 
levels, known as OMICS [38,39]. OMICS is broken down into four 
major categories: Genomics is the study of the genes; transcriptomics is 
the study of the mRNA; proteomics is the study of functional proteins, 
and metabolomics is the study of cellular metabolism. The use of 
OMICS has allowed the biomedical community to analyze the effects 
of the environment at the molecular and cellular levels in organisms in 
order to understand how the biological processes can be affected. This 
can lead to better risk assessments, accurate diagnoses of diseases, and 
the practice of personalized medicine in the future. 
Risk assessment is the measurement of adverse health effects 
in a population that is exposed to risk enhancing factors such as 
environmental contaminants. According to the Environmental 
Protection Agency (EPA) guidance, the four steps in risk assessment are 
described as the following: 1. Identify the hazard, 2. Examine the dose-
response relationship, 3. Exposure assessment and 4. Characterization 
risk [40]. However, current research shows a lack of OMICS usage in 
risk assessment. The EPA (2013) has reported that OMICS studies are 
lacking dose-response and don’t know which exposure dose causes an 
appearance of the first adverse effects. This may emphasize that OMICS 
technologies are lacking in risk assessment but other areas show great 
promise. 
Utilizing personalized medicine allows for risk evaluation, 
diagnosis, monitoring, and treatment of patients according to their 
specific genetic and molecular makeup. Chen et al. [41] has reported that 
“the disease risk can be evaluated from genome sequencing and shows 
how traits associated with diseases can be monitored to identify varying 
physiological stages”. They also stated that “detailed OMICS profiling 
with genomic sequencing can provide molecular and physiological 
information of medical significance”. Since the mitochondria are 
known for its dynamic nature, it can be mutated from environmental 
factors leading to certain neurological diseases. Genomics can be useful 
to identify biomarkers in people who suffer from Parkinson’s disease 
to assess risk, monitor prognosis, determine treatments, and possible 
preventions in the future. 
Outcomes
Advances in OMICS techniques have aided scientists to discover 
cellular mechanisms in how the physiological and molecular state 
changes in organisms with diseases. These advance technologies have 
allowed for identification of biomarkers that “can provide a window 
into disease mechanisms with hope of developing specific therapeutic 
targets of the disease”, as a stated by Caudle et al. [42]. Discovery of 
biomarkers will help scientist to know how the body functions in normal 
and disease states with hopes of formulating medicines. Their study also 
commented that, “OMICS techniques have been integral in confirming 
pathways that are associated with PD, including mitochondrial and 
proteasomes function and synaptic neurotransmission” [42]. With 
the advances in transcriptomics, proteomics, and metabolomics, it is 
possible to understand how the mitochondria function and relate to the 
development of PD. 
Transcriptomics is the study of mRNA. As it  relates to Parkinson’s 
Disease (PD), “disruption of the mitochondria’s function can have 
severe repercussions for the normal functioning of the dopamine 
neuron, through the suppression of energy production and generation 
of neurotoxic reactive oxygen species” [42]. This may lead to symptoms 
of neurodegenerative disease such as those seen in Alzheimer disease 
(AD), Huntington Disease (HD), and Parkinson Disease (PD). In 
support of this premise, Caudle et al. [43] has stated that “exposure 
of rats and mice to mitochondrial complex I inhibitors, rotenone and 
MPTP, causes considerable degeneration of dopamine neurons in SNpc, 
showing pathological features of PD”. Microarray analysis is a great 
technique used in analyzing mRNA expression that it can predict gene 
profile using clinical samples such as urine, blood, cerebrospinal fluid 
(CSF), and saliva. This technique has helped scientists discover certain 
biomarkers that are under-regulated in susceptible individuals who are 
prone to getting PD. Caudle et al. [42] has suggested that “microarray 
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analysis and blood from PD patients and controls have uncovered a 
significant clue in in the transcriptional modulation of α-synuclein: 
genetic alteration of α-synuclein can have deleterious effects on the 
risks of PD”. Understanding the mechanism of α-synuclein can assist 
with the invention of therapeutic medicines that suppress deregulation 
of α-synuclein and hopefully control the progression of PD. 
Proteomics is one of the most powerful technologies in the field 
of clinical research. It allows scientists to understand how proteins 
function in complex biological systems and how possible protein 
alterations underlie pathological processes. According to Caudle et 
al. [42] “the oxidation of DJ-1 could have significant consequences on 
its ability to function in attenuating the generation of oxidative stress 
within the dopamine neuron and Cu/ZN superoxide dismutase (SOD) 
serves to reduce the amount of intracellular oxidative stress, which can 
readily interact with other radicals to generate highly toxic reactive 
species”. Another discovery of a specific heat shock protein that can 
cause PD and mitochondrial repression is mortalin. It has been reported 
that “mortalin (also known as HSP70 or GRP75) expression was found 
to significantly reduce dopamine neurons in SNpc of PD patients 
compared with controls and is specific to mitochondrial fraction when 
biochemically isolated” [42].
From these findings, it was demonstrated that 72 other proteins 
have also been known to be altered in PD patients. Identification of 
these protein alterations can serve as biomarkers in understanding the 
mechanisms of cellular pathways providing future targeted treatments 
at mutated or altered proteins in transgenic animals or patients who 
suffer from PD. So far, proteomics and transcriptomics have uncovered 
a vast amount of credible scientific information regarding the intricacies 
of cellular function and the relationship between mitochondria and 
Parkinson’s.
Applying metabolomics can further advance the understanding 
of PD and mitochondria function. Metabolomics is the study of 
metabolism in the cellular pathways of organisms. It has been indicated 
that “reduction in uric acid and increase levels of glutathione and 
8-hydroxy- 2’-deoxyguanosine have contributed to the role of oxidative 
stress in PD” [42]. This suggests that PD patients display various levels 
of certain metabolites throughout the body that can disrupt oxidation 
leading to progression of PD. By knowing how these levels vary, 
researchers can create pharmacological remedies aimed at returning the 
levels to normal and perhaps completely preventing disease occurrence. 
With the application of OMICS, biomedical science has expanded the 
molecular understanding of mRNA, proteins, and metabolites and how 
their disturbances affects the mitochondrial function, leading to PD. 
Realizing this molecular network connection in the pathogenesis of PD 
would be beneficial to improve the risk assessment of the environmental 
factors for this disease. 
Potential Impacts
Research has shown that pesticides can cause mitochondrial 
disruption that can lead to the development of neurodegenerative 
diseases such as Alzheimer’s and Parkinson’s diseases [13]. OMICS 
technologies have gathered significant data showing how disruption in 
genes, proteins, metabolites, and cellular pathways affect mitochondrial 
function that the subsequent decrease in dopamine neurons. Thorough 
understanding of how Parkinson’s can develop has the potential to 
improve risk assessment and diagnosis.  This would greatly contribute 
to the preservation of public health. 
Some public health implications would be to resolve the issue by using 
alternative pesticides that contain safer environmental compounds. 
Pesticides contain a lot of hazardous substances and chemicals that 
can cause disruption in the cellular pathways. Pollutants or different 
toxicants can readily accumulate in mitochondrial membranes due to 
its high lipid content as seen with the antineoplastic agent, adriamycin. 
The lipid content facilitates the deposition of lipophilic compounds like 
polycyclic aromatic hydrocarbons and some alkylating agents [42,43]. 
Toxic metals like mercury, Iron, and manganese have also been known 
as risk factors in mitochondria dysfunction as well [44-46]. Another 
relevant plan of action is awareness of the exposure levels that can cause 
mitochondrial disruption leading to PD [47]. With this information 
researchers can develop appropriate therapies to block this disruption. 
Also, identification of biomarkers complimented by use of genetic 
mapping and genome-wide association studies (GWAS) would be 
good preventive counter-measures against Parkinson’s disease [48,49]. 
With the advances of OMICS technologies, it is possible to provide 
improved risk assessment, monitoring, and prevention planning. Once 
established, it is possible to use relevant biomarkers to detect cellular 
malfunctions and apply appropriate treatments. Understanding the 
underlying cellular mechanisms of PD and its interaction with certain 
environmental factors will prove advantageous to developing targeted 
treatments and also, prevent early-onset in young individuals.
Conclusion and Perspective
Parkinson’s disease (PD) is caused by mitochondrial dysfunction 
in relation to certain defects in proteins, cellular pathways, metabolites, 
and exposure to pesticides. The primary insult is reduced dopamine 
levels in the brain due to either biological or environmental factors. 
There is especially high risk of developing mitochondrial defects and 
resultant neurodegenerative disease with occupational exposure from 
pesticides. OMICS techniques have helped with identifying certain 
biomarkers with possibility of creating medicines that can help 
with prevention. OMICS has the potential to improve the quality of 
health care and alleviate the public health burden of disease through 
more advanced risk assessment and detection. Those afflicted with 
mitochondrial disorders will serve to benefit from OMICS strategies in 
development and maximization of targeted treatments.  The multiple 
biochemical and molecular techniques offered by the field of OMICS 
will prove to be advantageous for the biomedical and public health 
communities. Overall, the application of OMICS as an integrated 
molecular assessment tool for diagnostics by exploring biomarkers and 
disease management of Parkinson’s in early onset of pathogenesis can 
be beneficial in reducing occurrence in susceptible PD population.
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